We are now trying to apply the same strategy to assess the MHC-II immunopeptidome of CIITA-modified human glioblastomas, the most malignant tumor of the central nervous system, whose prognosis is dismal (less than 10% survival after five years from diagnosis) and for which new therapeutic approaches are urgently needed. This evidence concerns the gene CIITA and glioblastoma.